Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen receptor T-cell therapy, according to results of a retrospective cohort ...

Following the commercial launch in 2017 of partner Novartis’s CAR-T Kymriah (in r/r paediatric ALL), Oxford BioMedica plc (LON:OXB) has become one of a handful of regulatory... Oxford BioMedica ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

Winters did not stand for re-electionShareholders approved all other proposals by the Board of Directors, including the reduction of share capital, the 2024 report on Novartis announced today it ...